Chemical formula: C₁₄H₁₀BNO₃ Molecular mass: 251.05 g/mol PubChem compound: 44591583
Crisaborole is an anti-inflammatory benzoxaborole phosphodiesterase-4 (PDE4) inhibitor that suppresses secretion of certain cytokines, such as tumour necrosis factor-α (TNF-α), interleukins (IL-2, IL-4, IL-5), and interferon gamma (IFNγ), and improves skin barrier function as measured by transepidermal water loss (TEWL). It is used for treatment of mild to moderate atopic dermatitis in adults and paediatric patients.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| D11AH06 | D Dermatologicals → D11 Other dermatological preparations → D11A Other dermatological preparations → D11AH Agents for dermatitis, excluding corticosteroids | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| EUCRISA Ointment | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| STAQUIS Ointment | European Medicines Agency (EU) | MPI, EU: SmPC |
Crisaborole is an active ingredient of these brands:
United States (US)Austria (AT)Canada (CA)Estonia (EE)Hong Kong (HK)Israel (IL)Lithuania (LT)Poland (PL)South Africa (ZA)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
